Fate Therapeutics FATE 深 滬
已收盤 08-08 16:00:00 美东时间
0.9214
-0.059
-5.99%
華盛通- 最 高0.9904
- 今 開0.98
- 成交量 140.53万股
- 最 低 0.92
- 昨 收 0.9801
- 總市值 1.06亿
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.6611
- 委 比 97.55%
- 總股本 1.15亿
- 歷史最高 121.16
- 量 比 1.39
- 振 幅 7.18%
- 歷史最低 0.6611
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OSR appoints Andreas Niethammer as Chief Medical Officer of Vaximm AG
OSR Holdings (NASDAQ:OSRH) announced on Tuesday the appointment of Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR company developing a platform of orally administered target-specific...
07-15 19:58
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics granted 30,000 stock options with a $1.12 exercise price and 37,900 RSUs to new employees on July 2, 2025, under its equity plan. These grants were approved by the Compensation Committee as inducements for employment. Options and RSUs vest over four years, with 25% vesting annually and the remainder in monthly installments, contingent on continuous employment.
07-03 17:05
Fate Therapeutics Announces New And Updated Clinical Data From First Five Patients Dosed With FT819 For Treatment Of Moderate-To-Severe SLE, At EULAR 2025 Congress
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in
06-11 21:02
Bell Media Announces 2025/26 Original Content Slate
– Bell Media's initial 2025/26 slate includes 116 titles, a nearly 20% increase over last year – – More titles to be announced later this year – Key Tags: @BellMediaPR, @TheLede_CA TORONTO, ...
06-05 19:30
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
Fate Therapeutics announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors, effective May 29, 2025. Mr. Abernethy brings over 15 years of experience in corporate finance and investor relations in the biotech and medical device industry. He replaces Timothy P. Coughlin, who has stepped down from the Board. The company highlighted Mr. Abernethy's expertise in capital strategy and long-term planning, emphasizing his potentia...
05-30 20:30
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Fate Therapeutics将展示其针对中重度系统性红斑狼疮的1期临床试验数据，突出无氟达拉滨治疗方案的安全性和疗效。会议于6月11日至14日在巴塞罗那举行，公司还将介绍其基于iPSC的CAR-T和CAR-NK细胞平台的预clinical研究，强调Sword和Shield技术在无需化疗条件下的潜在优势。
05-28 21:54
Baird Maintains Neutral on Fate Therapeutics, Lowers Price Target to $4
Baird analyst Jack Allen maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target from $5 to $4.
05-14 21:14
Needham Reiterates Hold on Fate Therapeuticsto Hold
Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.
05-14 19:31
